Startups
KannaLife Sciences, Inc. is a bio-pharmaceutical and phyto-medical company involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. KannaLife Sciences currently holds an exclusive license with National Institutes of Health – Office of Technology Transfer (NIH-OTT) for the Commercialization of U.S. Patent 6,630,507, Cannabinoids as Antioxidants and Neuroprotectants (the 507 Patent). KannaLife is currently conducting research and development at the Bucks County Biotechnology Center in Doylestown, PA, for a target drug candidate to treat Hepatic Encephalopathy (HE). HE is an oxidative stress related disease that affects the cognitive and behavioral functions, and the wellness of the brain. #6630507, 6630507
Overview
Employees
1-10
Total raised
$1.5M
Founded date
2010
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 2
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 7, 2013 | KannaLife Sciences Raises $1.5M in Series A Financing | KannaLife Sciences, Inc., a West Hills, NY-based phyto-medical company that specializes in the research & development of pharmacological products derived from botanical sources, raised $1.5m in Series A financing. The round was led by a... |
Reviews 0
FAQ about Kannalife Sciences, Inc.
When was Kannalife Sciences, Inc. founded?
Kannalife Sciences, Inc. was founded in 2010.
How much funding has Kannalife Sciences, Inc. raised?
Kannalife Sciences, Inc. has raised $1.5M in total across 1 funding round.
What has the press written about Kannalife Sciences, Inc.?
Parsers VC has collected 2 articles mentioning Kannalife Sciences, Inc., among them “KannaLife Sciences Raises $1.5M in Series A Financing” (Mar 7, 2013).
Is Kannalife Sciences, Inc. still active?
Yes, Kannalife Sciences, Inc. is active; its latest activity on Parsers VC dates from Jun 25, 2024.